Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia

William Wierda, Susan O'Brien, Sijin Wen, Stefan Faderl, Guillermo Garcia-Manero, Deborah Thomas, Kim Anh Do, Jorge Cortes, Charles Koller, Miloslav Beran, Alessandra Ferrajoli, Francis Giles, Susan Lerner, Maher Albitar, Hagop Kantarjian, Michael Keating

Research output: Contribution to journalArticle

Abstract

Purpose: The efficacy, toxicity, and tolerability of chemoimmunotherapy with the combination of fludarabine, cyclophosphamide, and rituximab (FCR) were evaluated in previously treated patients with chronic lymphocytic leukemia (CLL). The purpose of this study was to improve the complete remission (CR) rate for previously treated patients and evaluate the quality of bone marrow response. Patients and Methods: One hundred seventy-seven previously treated patients with CLL were evaluated. Treatment consisted of rituximab 375 mg/m 2 day 1 of course 1 and 500 mg/m2 day 1 of courses 2 to 6; fludarabine 25 mg/m2/d days 2 to 4 of course 1 and days 1 to 3 of courses 2 to 6; and cyclophosphamide 250 mg/m2/d days 2 to 4 of course 1 and days 1 to 3 of courses 2 to 6. Courses were repeated every 4 weeks. Results: CR was achieved in 25% of 177 patients, and nodular partial remission and partial remission were achieved in 16% and 32% of patients, respectively; the overall response rate was 73%. Twelve (32%) of 37 complete responders tested achieved molecular remission in bone marrow. Univariate and multivariate analyses were used to identify pretreatment patient characteristics associated with CR and overall remission, longer time to progression, and overall survival. Conclusion: The FCR regimen was an active and well-tolerated treatment for previously treated patients with CLL. Myelosuppression was the most common toxicity. FCR induced the highest CR rate reported in a clinical trial of previously treated patients with CLL. Furthermore, molecular remissions were achieved in a third of patients achieving CR.

Original languageEnglish (US)
Pages (from-to)4070-4078
Number of pages9
JournalJournal of Clinical Oncology
Volume23
Issue number18
DOIs
StatePublished - Dec 1 2005
Externally publishedYes

Fingerprint

B-Cell Chronic Lymphocytic Leukemia
Cyclophosphamide
Bone Marrow
fludarabine
Rituximab
Multivariate Analysis
Clinical Trials
Survival

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. / Wierda, William; O'Brien, Susan; Wen, Sijin; Faderl, Stefan; Garcia-Manero, Guillermo; Thomas, Deborah; Do, Kim Anh; Cortes, Jorge; Koller, Charles; Beran, Miloslav; Ferrajoli, Alessandra; Giles, Francis; Lerner, Susan; Albitar, Maher; Kantarjian, Hagop; Keating, Michael.

In: Journal of Clinical Oncology, Vol. 23, No. 18, 01.12.2005, p. 4070-4078.

Research output: Contribution to journalArticle

Wierda, W, O'Brien, S, Wen, S, Faderl, S, Garcia-Manero, G, Thomas, D, Do, KA, Cortes, J, Koller, C, Beran, M, Ferrajoli, A, Giles, F, Lerner, S, Albitar, M, Kantarjian, H & Keating, M 2005, 'Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia', Journal of Clinical Oncology, vol. 23, no. 18, pp. 4070-4078. https://doi.org/10.1200/JCO.2005.12.516
Wierda, William ; O'Brien, Susan ; Wen, Sijin ; Faderl, Stefan ; Garcia-Manero, Guillermo ; Thomas, Deborah ; Do, Kim Anh ; Cortes, Jorge ; Koller, Charles ; Beran, Miloslav ; Ferrajoli, Alessandra ; Giles, Francis ; Lerner, Susan ; Albitar, Maher ; Kantarjian, Hagop ; Keating, Michael. / Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. In: Journal of Clinical Oncology. 2005 ; Vol. 23, No. 18. pp. 4070-4078.
@article{3c2a2a81e1e1448480ac54e0440825aa,
title = "Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia",
abstract = "Purpose: The efficacy, toxicity, and tolerability of chemoimmunotherapy with the combination of fludarabine, cyclophosphamide, and rituximab (FCR) were evaluated in previously treated patients with chronic lymphocytic leukemia (CLL). The purpose of this study was to improve the complete remission (CR) rate for previously treated patients and evaluate the quality of bone marrow response. Patients and Methods: One hundred seventy-seven previously treated patients with CLL were evaluated. Treatment consisted of rituximab 375 mg/m 2 day 1 of course 1 and 500 mg/m2 day 1 of courses 2 to 6; fludarabine 25 mg/m2/d days 2 to 4 of course 1 and days 1 to 3 of courses 2 to 6; and cyclophosphamide 250 mg/m2/d days 2 to 4 of course 1 and days 1 to 3 of courses 2 to 6. Courses were repeated every 4 weeks. Results: CR was achieved in 25{\%} of 177 patients, and nodular partial remission and partial remission were achieved in 16{\%} and 32{\%} of patients, respectively; the overall response rate was 73{\%}. Twelve (32{\%}) of 37 complete responders tested achieved molecular remission in bone marrow. Univariate and multivariate analyses were used to identify pretreatment patient characteristics associated with CR and overall remission, longer time to progression, and overall survival. Conclusion: The FCR regimen was an active and well-tolerated treatment for previously treated patients with CLL. Myelosuppression was the most common toxicity. FCR induced the highest CR rate reported in a clinical trial of previously treated patients with CLL. Furthermore, molecular remissions were achieved in a third of patients achieving CR.",
author = "William Wierda and Susan O'Brien and Sijin Wen and Stefan Faderl and Guillermo Garcia-Manero and Deborah Thomas and Do, {Kim Anh} and Jorge Cortes and Charles Koller and Miloslav Beran and Alessandra Ferrajoli and Francis Giles and Susan Lerner and Maher Albitar and Hagop Kantarjian and Michael Keating",
year = "2005",
month = "12",
day = "1",
doi = "10.1200/JCO.2005.12.516",
language = "English (US)",
volume = "23",
pages = "4070--4078",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "18",

}

TY - JOUR

T1 - Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia

AU - Wierda, William

AU - O'Brien, Susan

AU - Wen, Sijin

AU - Faderl, Stefan

AU - Garcia-Manero, Guillermo

AU - Thomas, Deborah

AU - Do, Kim Anh

AU - Cortes, Jorge

AU - Koller, Charles

AU - Beran, Miloslav

AU - Ferrajoli, Alessandra

AU - Giles, Francis

AU - Lerner, Susan

AU - Albitar, Maher

AU - Kantarjian, Hagop

AU - Keating, Michael

PY - 2005/12/1

Y1 - 2005/12/1

N2 - Purpose: The efficacy, toxicity, and tolerability of chemoimmunotherapy with the combination of fludarabine, cyclophosphamide, and rituximab (FCR) were evaluated in previously treated patients with chronic lymphocytic leukemia (CLL). The purpose of this study was to improve the complete remission (CR) rate for previously treated patients and evaluate the quality of bone marrow response. Patients and Methods: One hundred seventy-seven previously treated patients with CLL were evaluated. Treatment consisted of rituximab 375 mg/m 2 day 1 of course 1 and 500 mg/m2 day 1 of courses 2 to 6; fludarabine 25 mg/m2/d days 2 to 4 of course 1 and days 1 to 3 of courses 2 to 6; and cyclophosphamide 250 mg/m2/d days 2 to 4 of course 1 and days 1 to 3 of courses 2 to 6. Courses were repeated every 4 weeks. Results: CR was achieved in 25% of 177 patients, and nodular partial remission and partial remission were achieved in 16% and 32% of patients, respectively; the overall response rate was 73%. Twelve (32%) of 37 complete responders tested achieved molecular remission in bone marrow. Univariate and multivariate analyses were used to identify pretreatment patient characteristics associated with CR and overall remission, longer time to progression, and overall survival. Conclusion: The FCR regimen was an active and well-tolerated treatment for previously treated patients with CLL. Myelosuppression was the most common toxicity. FCR induced the highest CR rate reported in a clinical trial of previously treated patients with CLL. Furthermore, molecular remissions were achieved in a third of patients achieving CR.

AB - Purpose: The efficacy, toxicity, and tolerability of chemoimmunotherapy with the combination of fludarabine, cyclophosphamide, and rituximab (FCR) were evaluated in previously treated patients with chronic lymphocytic leukemia (CLL). The purpose of this study was to improve the complete remission (CR) rate for previously treated patients and evaluate the quality of bone marrow response. Patients and Methods: One hundred seventy-seven previously treated patients with CLL were evaluated. Treatment consisted of rituximab 375 mg/m 2 day 1 of course 1 and 500 mg/m2 day 1 of courses 2 to 6; fludarabine 25 mg/m2/d days 2 to 4 of course 1 and days 1 to 3 of courses 2 to 6; and cyclophosphamide 250 mg/m2/d days 2 to 4 of course 1 and days 1 to 3 of courses 2 to 6. Courses were repeated every 4 weeks. Results: CR was achieved in 25% of 177 patients, and nodular partial remission and partial remission were achieved in 16% and 32% of patients, respectively; the overall response rate was 73%. Twelve (32%) of 37 complete responders tested achieved molecular remission in bone marrow. Univariate and multivariate analyses were used to identify pretreatment patient characteristics associated with CR and overall remission, longer time to progression, and overall survival. Conclusion: The FCR regimen was an active and well-tolerated treatment for previously treated patients with CLL. Myelosuppression was the most common toxicity. FCR induced the highest CR rate reported in a clinical trial of previously treated patients with CLL. Furthermore, molecular remissions were achieved in a third of patients achieving CR.

UR - http://www.scopus.com/inward/record.url?scp=23044501404&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=23044501404&partnerID=8YFLogxK

U2 - 10.1200/JCO.2005.12.516

DO - 10.1200/JCO.2005.12.516

M3 - Article

C2 - 15767647

AN - SCOPUS:23044501404

VL - 23

SP - 4070

EP - 4078

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 18

ER -